OSIVAX

NAME OF THE CEO
Alexandre LE VERT

ADRESS
99, rue de Gerland
69007 Lyon - FRANCE

EMAIL
alevert@osivax.com

www.osivax.com

MANAGEMENT TEAM
CEO and Co-founder : M. Alexandre Le Vert
Chief Development Officer and Co-founder : Dr Florence Nicolas
CSO and Co-founder : Dr Fergal Hill
Chief Business Development Officer : Dr Delphine Guyon-Gellin
Medica Director (Acting) : Dr Simonetta Viviani

TARGETED MARKET
First, influenza vaccination, a $4B market with a significant unmet medical need. Then, vaccination in general ($30B) and cancer immunotherapies.

PRIVATE COMPANY
CREATION DATE
June 2017

MISSION
• Disrupt influenza prevention, with a universal Flu vaccine to be combined with commercialized Flu vaccines to drastically improve efficacy.
• Develop vaccines against infectious diseases and cancer immunotherapies, using a unique and proprietary technology platform triggering CD8 T-cell immunity.

TECHNOLOGY
• OVX836, a universal influenza vaccine candidate that is starting a phase I trial.
• oligoDOM®, a patented technology platform eliciting powerful CD8 T-cell responses, to develop unadjuvanted subunit vaccines and immunotherapies.

COMPETITION
In influenza, Vaccitech is a potential competitor targeting the same approach but with a different mechanism of action. Their vaccine candidate is currently in phase II. As we position our universal flu vaccine in combination with current and future seasonal vaccines, we do not consider them as competitors.

ALLIANCES/PARTNERSHIPS
OligoDOM®, our technology platform, is partnered to academic and industrial partners on a field by field basis (Oxford University – UK, DKFZ in Heidelberg – Germany, undisclosed industrial partner).
The influenza vaccine candidate is not partnered today.
UPCOMING CATALYSTS

Initial results of the phase I trial in influenza in Q1 2019.

SHAREHOLDERS (percentage)

- Luzac Innovation (A. Le Vert)
- Pradeyrol Développement
- Florence Nicolas
- Business Angels
- Stock option pool
- Objectif Osivax (Anaxago)

PISTOL

<table>
<thead>
<tr>
<th>Disease</th>
<th>Research</th>
<th>PC</th>
<th>Phase I</th>
<th>Leader</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal Flu</td>
<td></td>
<td></td>
<td>2018</td>
<td>OSIVAX Leading program</td>
</tr>
<tr>
<td>Immuno- oncology</td>
<td></td>
<td></td>
<td></td>
<td>OSIVAX</td>
</tr>
<tr>
<td>Confidential</td>
<td></td>
<td></td>
<td></td>
<td>Big Pharma</td>
</tr>
<tr>
<td>Malaria (TBV2)</td>
<td></td>
<td></td>
<td></td>
<td>OSIVAX</td>
</tr>
<tr>
<td>HPV2</td>
<td></td>
<td></td>
<td></td>
<td>OSIVAX</td>
</tr>
</tbody>
</table>